A recent study published in the Annals of Internal Medicine reveals a notable shift in the prescription patterns of GLP-1 medications, which were originally designed for individuals with type 2 diabetes. The research indicates that the number of prescriptions for GLP-1 drugs for those without diabetes is on the rise, while new prescriptions for diabetic patients are decreasing.
GLP-1 medications, such as Wegovy and Ozempic, function by imitating a hormone that manages blood sugar levels and curbs appetite. Their use has expanded beyond diabetes treatment, as the FDA approved Wegovy for weight management in 2021. Currently, leading pharmaceutical companies like Novo Nordisk and Eli Lilly are facing challenges in meeting the soaring demand for these drugs.
The study analyzed medical records from over 45 million Americans between 2011 and 2023, noting that the percentage of new GLP-1 users with type 2 diabetes has declined from nearly 90% in 2019 to over 70% in 2023. In contrast, the proportion of new users without type 2 diabetes rose from 10% to 25%. Yee Hui Yeo, one of the study’s authors, highlighted that while more healthcare providers are recognizing the benefits of these medications for obesity treatment, this trend poses potential risks for medication shortages and accessibility for diabetic patients.
Data suggests that GLP-1 drugs are increasingly popular due to their effectiveness in aiding weight loss, with users reportedly shedding up to 26% of their body weight. This growing demand has propelled Eli Lilly and Novo Nordisk to the forefront of the pharmaceutical industry, but it has also led to difficulties in some patients obtaining their prescriptions. Both companies are making substantial investments to increase production capacity.
Looking ahead, Morgan Stanley estimates that the global market for GLP-1 medications could reach $105 billion by 2030, with the U.S. adoption potentially rising to about 31.5 million individuals, or roughly 9% of the population, by 2035. This upward trend in GLP-1 usage underscores a significant shift in how these medications are perceived and utilized, particularly in the fight against obesity.
In summary, while the increasing use of GLP-1 medications for weight management signals progress in addressing obesity, it also raises essential questions regarding the availability of these drugs for those who need them most, particularly diabetic patients. It emphasizes the importance of balancing treatment needs across various patient populations in the face of growing demand and potential supply constraints.